Orion: Phase III Trial With Darolutamide Meets Primary Endpoint In MHSPC
3/12 08:19
(RTTNews) - Orion Oyj announced Orion's and Bayer's (BAYZF.PK, BAYRY.PK, BYR.L) phase III ARASENS trial showed an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy compared to docetaxel and androgen deprivation the...